RESEARCH PROFILE
KISSPEPTIN
Reproductive Neuroendocrine Signaling Peptide
Kisspeptin is an endogenous signaling peptide that helps regulate the hypothalamic-pituitary-gonadal axis. By activating the kisspeptin receptor, it stimulates GnRH signaling and downstream release of luteinizing hormone and follicle-stimulating hormone.
Human research has examined kisspeptin in reproductive endocrinology, fertility signaling, hypothalamic amenorrhea, sexual behavior, and controlled IVF research.
INVESTIGATIONAL • NOT FDA APPROVED • HUMAN CLINICAL RESEARCH
KISSPEPTIN AT A GLANCE
Category
Reproductive neuroendocrine peptide
Primary Target
Kisspeptin receptor • KISS1R/GPR54
Primary Pathway
Kisspeptin → GnRH → LH / FSH → gonadal hormone signaling
Research Forms
Kisspeptin-10 • Kisspeptin-54
Human Evidence
Controlled human endocrine and reproductive research
Regulatory Status
Investigational • Not FDA approved
IMPORTANT DISTINCTION
Kisspeptin-10 and Kisspeptin-54 are different peptide forms and should not be treated as interchangeable.
Your Project profile identifies Kisspeptin-10 as a shorter-acting form commonly encountered in research-supply settings.
Much of the better-developed human fertility and IVF literature has instead investigated Kisspeptin-54.
Findings from one form should therefore not automatically be assigned to the other.
WHAT IS KISSPEPTIN?
Kisspeptin is a naturally occurring peptide signaling system involved in control of human reproductive function.
It acts near the top of the hypothalamic-pituitary-gonadal, or HPG, axis.
Kisspeptin binds to the receptor commonly known as KISS1R or GPR54, which helps stimulate hypothalamic neurons involved in gonadotropin-releasing hormone signaling.
GnRH then signals the pituitary gland to release:
Luteinizing hormone, or LH
Follicle-stimulating hormone, or FSH
These hormones subsequently influence reproductive function in both men and women.
In men, LH signaling can stimulate the testes to produce testosterone.
In women, LH and FSH participate in ovarian function, follicular development, ovulation, and reproductive cycling.
Kisspeptin therefore acts as an upstream reproductive signal rather than functioning as testosterone, estrogen, LH, FSH, or GnRH itself.
MECHANISM OF ACTION
Kisspeptin functions as an upstream regulator of reproductive endocrine signaling.
KISS1R / GPR54
Kisspeptin binds to the KISS1 receptor, also known as GPR54.
Activation of this receptor initiates signaling involved in stimulating GnRH neurons.
GnRH SIGNALING
GnRH is released from the hypothalamus and signals the anterior pituitary.
Kisspeptin therefore operates upstream of GnRH rather than directly stimulating the testes or ovaries.
LH & FSH
Pituitary GnRH signaling stimulates release of:
LH
FSH
These gonadotropins carry the reproductive signal downstream.
GONADAL RESPONSE
In men, LH can stimulate Leydig cells within the testes to produce testosterone.
FSH contributes to spermatogenic signaling.
In women, LH and FSH participate in follicular development, ovarian steroidogenesis, and ovulation.
PHYSIOLOGICAL FEEDBACK
The reproductive axis is governed by complex feedback between the hypothalamus, pituitary gland, gonads, and circulating sex hormones.
Kisspeptin does not bypass this entire system.
Instead, it stimulates an upstream signaling pathway that still depends on functioning downstream endocrine tissues.
WHAT THE RESEARCH SHOWS
Kisspeptin has meaningful human research, particularly in reproductive endocrinology. However, the evidence differs considerably by peptide form, route of administration, population, and research objective.
HUMAN ENDOCRINE RESEARCH
Controlled human studies have demonstrated that kisspeptin administration can stimulate the reproductive hormone axis.
Research comparing Kisspeptin-10, Kisspeptin-54, and GnRH has shown increases in downstream gonadotropin signaling, particularly LH.
The response can differ depending on the kisspeptin form and method of administration.
MALE HORMONE SIGNALING
Your Project profile cites human research in healthy men in which Kisspeptin-10 infusion increased LH and was followed by increased testosterone.
This supports a physiological relationship between kisspeptin signaling and the male reproductive axis.
However, kisspeptin is not testosterone replacement therapy.
An increase in testosterone depends on an intact downstream response from the pituitary and testes.
HYPOTHALAMIC AMENORRHEA
Kisspeptin has been investigated in women with hypothalamic amenorrhea, a condition involving impaired hypothalamic reproductive signaling.
Subcutaneous Kisspeptin-54 has been shown to stimulate LH pulses in this research setting.
These studies helped establish the role of kisspeptin as an important regulator of GnRH and reproductive hormone signaling.
IVF & OOCYTE MATURATION
One of the most developed areas of human kisspeptin research involves assisted reproduction.
Clinical studies have investigated Kisspeptin-54 as a trigger for oocyte maturation before egg retrieval during IVF.
Research has demonstrated successful egg maturation following Kisspeptin-54 administration.
Some studies have explored whether this approach may reduce the risk of ovarian hyperstimulation syndrome, or OHSS, in selected high-risk IVF populations.
This research involves Kisspeptin-54 under controlled fertility-treatment protocols and should not be generalized to Kisspeptin-10 research products.
SEXUAL BEHAVIOR & DESIRE
Human studies have also examined kisspeptin signaling in sexual and emotional processing.
Your Project source cites randomized research involving men and women with hypoactive sexual desire disorder, in which intravenous Kisspeptin-54 altered neural responses and some measures associated with sexual processing.
This remains an area of investigation rather than an established approved treatment.
DESENSITIZATION
An important feature of kisspeptin biology is that more stimulation does not necessarily mean a stronger or sustained response.
Your Project profile specifically notes that repeated or continuous exposure may lead to desensitization or tachyphylaxis, with fading LH responsiveness.
This is one reason acute or pulsatile research findings should not automatically be extrapolated to chronic exposure.
IMPORTANT EVIDENCE LIMITATIONS
Human research exists, but much of the strongest evidence involves:
Kisspeptin-54 rather than Kisspeptin-10
Intravenous administration
Short-term endocrine experiments
Closely monitored fertility protocols
Specific reproductive disorders
There is no completed Phase III development program, no FDA-approved kisspeptin drug, and limited long-term safety evidence in the Project source.
Claims involving testosterone optimization, TRT replacement, fertility treatment, libido enhancement, or chronic hormone restoration therefore extend beyond what the evidence currently establishes.
SAFETY & RESEARCH CONSIDERATIONS
Published short-term human studies of Kisspeptin-10 and Kisspeptin-54 have generally reported good tolerability, but the long-term safety database is limited.
REPORTED EFFECTS
Your Project profile identifies reported effects including:
Mild flushing or warmth after administration
Mild injection-site redness or irritation
Transient headache
Brief mild nausea
Short-lived increases in LH and FSH are expected pharmacodynamic effects rather than necessarily adverse reactions.
HORMONAL EFFECTS
Because kisspeptin directly influences reproductive endocrine signaling, changes in downstream sex hormones may occur.
In men with intact testicular function, increased LH signaling may subsequently increase testosterone.
Hormonal responses can vary considerably by individual and clinical context.
DESENSITIZATION
Repeated or prolonged stimulation may reduce LH responsiveness.
This phenomenon is described as desensitization or tachyphylaxis.
The Project profile therefore specifically cautions against assuming that continuous exposure will produce continuously increasing reproductive hormone signaling.
PREGNANCY & REPRODUCTIVE CONTEXT
Kisspeptin participates directly in reproductive physiology.
Your Project source notes insufficient safety evidence for unsupervised use during pregnancy or breastfeeding.
Pregnancy status and fertility objectives materially change the clinical context of manipulating this pathway.
HORMONE-SENSITIVE CONDITIONS
Because kisspeptin can alter downstream reproductive hormone signaling, the Project source advises caution in hormone-sensitive conditions.
PITUITARY OR GONADAL DISEASE
Kisspeptin depends on downstream pituitary and gonadal function.
A person whose pituitary gland cannot appropriately release LH or FSH, or whose gonads cannot respond to those signals, may not respond normally to upstream kisspeptin stimulation.
LONG-TERM UNCERTAINTY
Your Project source emphasizes that long-term human safety data remain limited.
Possible cardiovascular concerns have been discussed largely from animal data, while the human relevance remains unclear.
The consequences of prolonged continuous kisspeptin exposure also remain insufficiently characterized.
REGULATORY CONTEXT
KISSPEPTIN IS NOT FDA APPROVED
No kisspeptin product is currently identified in your Project source as FDA approved for any indication.
Kisspeptin-10 should therefore be presented as an investigational research peptide, not as an approved fertility, testosterone, libido, or reproductive treatment.
NO APPROVED KISSPEPTIN DRUG
Your Project profile states that, as of its June 2026 regulatory review:
No kisspeptin product is FDA approved for any use
and
Kisspeptin is not approved as a drug in the European Union or Japan
COMPOUNDING REVIEW
Your Project source also documents an important U.S. regulatory development.
In October 2024, the FDA Pharmacy Compounding Advisory Committee reviewed Kisspeptin-10 for potential inclusion on the 503A Bulks List.
The committee voted against adding Kisspeptin-10.
According to the Project profile, concerns included:
Limited safety and effectiveness data
No approved kisspeptin product elsewhere in the world
Limited public quality data
Potential signal fading with chronic exposure
Animal safety concerns
This committee review should not itself be described as FDA approval or as proof that Kisspeptin-10 is unsafe. It reflects the regulatory committee's assessment of the evidence available for that compounding question.
RESEARCH PRODUCT DISTINCTION
A research-supply Kisspeptin-10 product is not an FDA-approved prescription medication.
Terms such as "research use only" also do not transform an investigational compound into an approved therapeutic product.
Research findings should not be interpreted as regulatory approval or individualized medical guidance.
ANALYTICAL DOCUMENTATION
Croix maintains available third party analytical documentation only for specific samples and lots that can be matched to corresponding laboratory reports.
LOT SPECIFIC ANALYTICAL DOCUMENTATION
Analytical documentation is displayed only when Croix has a corresponding laboratory report that can be matched to the specific product and lot.
No matching Kisspeptin COA is currently displayed.
IMPORTANT COA LIMITATION
When analytical documentation becomes available, results should apply only to the specific sample identified in the corresponding laboratory report.
A Certificate of Analysis for one sample does not establish the composition, purity, sterility, safety, efficacy, or characteristics of another sample, lot, batch, or product.
Croix requires the product, strength, lot or batch, sample ID, laboratory, and report date to be matched before analytical documentation is represented as supporting a product.
A passing COA does not establish FDA approval, clinical efficacy, medical suitability, or the characteristics of unrelated lots.
SELECTED RESEARCH & REFERENCES
Jayasena CN, Abbara A, Comninos AN, et al.
Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilisation.
Human clinical research evaluating Kisspeptin-54 as an oocyte-maturation trigger.
Abbara A, Jayasena CN, Christopoulos G, et al.
Research evaluating Kisspeptin-54 for oocyte maturation in women at high risk of ovarian hyperstimulation syndrome during IVF.
Comninos AN, Dhillo WS, et al.
Randomized clinical research examining kisspeptin administration in women with hypoactive sexual desire disorder.
Thurston L, Hunjan T, Ertl N, et al.
Randomized clinical research examining kisspeptin and sexual/emotional processing in men with hypoactive sexual desire disorder.
George JT, Veldhuis JD, Roseweir AK, et al.
Human research demonstrating that Kisspeptin-10 can stimulate LH secretion and alter reproductive hormone signaling in healthy men.
Jayasena CN, Nijher GMK, Chaudhri OB, et al.
Human research examining Kisspeptin-54 and gonadotropin secretion in women with hypothalamic amenorrhea.
U.S. Food & Drug Administration
FDA Pharmacy Compounding Advisory Committee materials concerning Kisspeptin-10 and the 503A Bulks List.
EVIDENCE NOTE
Kisspeptin has genuine human reproductive-endocrine research.
However, the specific peptide form matters.
Many prominent fertility and reproductive studies involve Kisspeptin-54, while the Croix research catalog identifies Kisspeptin-10. Findings should therefore remain attributed to the form actually studied.
RESEARCH & EDUCATIONAL INFORMATION
This profile is provided for research and educational reference. It does not constitute individualized medical advice or establish Kisspeptin-10 as safe or effective for personal use.
Kisspeptin is an important physiological regulator of the human reproductive endocrine axis, and multiple forms of kisspeptin have been investigated in controlled human studies.
No kisspeptin product is FDA approved for therapeutic use.
Research involving Kisspeptin-54 should not automatically be interpreted as evidence for Kisspeptin-10, and findings from controlled fertility or endocrine studies should not be generalized to unsupervised hormone, fertility, testosterone, or sexual-function use.
Analytical documentation presented by Croix applies only to the specific samples and lots identified in corresponding laboratory reports.